MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9+ monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer
Triple-negative breast cancer (TNBC) has high rates of recurrence despite chemotherapy and immune checkpoint blockade (ICB). Tumor-associated macrophages (TAMs) can either suppress or support antitumor immunity, but the mechanisms governing these states and therapeutic targets remain unclear. Here, integrating public s...